AUTHORS
Benjamin Hane, Emily Casteen2, Isuru Ratnayake, PhD3, Jianzheng Wu4, Dinesh Pal Mudaranthakam, PhD5, Al-Ola Abdallah, MD6, Zahra Mahmoudjafari, PharmD, BCOP7, Chiranjeevi Sainatham, MD8, Muhammad Mushtaq, MD9, Rajat Bansal, MD10, Yasser K Khaled, MD11, Joseph P McGuirk, DO12, Nausheen Ahmed, MD13, Forat Lutfi, MD14
AFFILIATIONS
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 Tufts Medical Center, Boston, Massachusetts, United States
3 University of Kansas Medical Center, Kansas City, United States
4 University of Kansas Medical Center, Kansas City, United States
5 University of Kansas Medical Center, Kansas City, United States
6 University of Kansas Medical Center, Kansas City, Kansas, United States
7 University of Kansas Medical Center, Kansas City, Kansas, United States
8 University of Florida, Gainesville, United States
9 University of Kansas Medical Center, Kansas City, Kansas, United States
10 University of Kansas Medical Center, Kansas City, Kansas, United States
11 Orlando Health Cancer Institute, Orlando, United States
12 University of Kansas Medical Center, Kansas City, Kansas, United States
13 Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
14 University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Introduction
In June 2025, the U.S. Food and Drug Administration eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirements for chimeric antigen receptor T-cell (CAR-T) therapies. Their removal reflected growing clinical experience, improved management of unique toxicities, and emerging real-world evidence that new-onset toxicities are uncommon beyond 14 days after infusion. In addition to reducing administrative requirements for authorized treatment centers (ATC), REMS elimination was intended to decrease health-system burden and improve patient access to CAR-T therapy.
Following REMS elimination, product labeling, and institutional practice, the recommended period for patients to remain near the ATC after CAR-T infusion shifted from 28 days to 14 days. Although this change may reduce travel, lodging, caregiver, and operational barriers, its implementation requires careful evaluation to ensure that shorter ATC-based monitoring does not compromise early patient safety. Limited post-implementation data exist comparing outcomes under 14-day versus 28-day monitoring. This study compared early safety and survival outcomes of adult patients managed with 14-day versus 28-day ATC monitoring after CAR-T infusion.
Methods
We reviewed?100 consecutive adult patients who underwent CAR-T therapy at the University of Kansas Health System (KU). Patients treated after REMS elimination formed the 14-day cohort, and those treated before comprised the 28-day cohort. Continuous and categorical variables were compared using parametric or nonparametric tests. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods and compared with log-rank testing. Logistic regression was used to assess the association between monitoring cohort and 30-day unplanned readmission after adjusting for treatment setting. All tests were two-sided with an alpha value of 0.05.?
Results
One hundred patients were evaluated: 51 in the Day-14 cohort and 49 in the Day-28 group. In the Day-14 cohort, 44/51 (86.3%) returned to their referring provider after day 14; of the 7 who did not, 3 were hospitalized with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), 3 had disease progression managed at KU, and 1 elected to stay at KU. Baseline age and sex were similar between cohorts but differed in disease (p=0.008) and treatment setting, inpatient or outpatient (p=0.041). Products (Day-14 vs Day-28): ciltacabtagene autoleucel 22/30, lisocabtagene maraleucel 21/12, axicabtagene ciloleucel 5/3, brexucabtagene autoleucel 0/4, tisagenlecleucel 2/0, idecabtagene vicleucel 1/0.
No deaths occurred within 30 days of CAR-T in either cohort, and severe toxicity was not increased with shorter monitoring: grade ≥3 Cytokine Release Syndrome (CRS) was rare in both groups (1 [2.0%] Day-14 vs. 0 Day-28), while grade ≥3 ICANS (3 [5.9%] vs. 8 [16.3%]) and ICU admission (7.0% vs. 21.4%, p=0.056) were lower in the Day-14 cohort, although differing disease mix (more myeloma in the Day-28 group) may have contributed. Rates of any CRS (64.7% vs. 75.5%, p=0.239), any ICANS (29.4% vs. 34.7%, p=0.571), and 30-day infection (11.8% vs. 14.3%, p=0.708) were comparable, as were 90-day OS (93.7% vs. 95.8%; log-rank p=0.655) and PFS (87.5% vs. 81.2%; log-rank p=0.369).
30-day unplanned readmission (54.9% vs. 36.7%, p=0.068) was numerically higher in the Day-14 cohort, but this difference appeared to be driven by treatment setting rather than monitoring duration (Day-14: 74.1% [20/27] outpatient vs. 33.3% [8/24] inpatient; Day-28: 81.2% [13/16] vs. 15.2% [5/33]), and the Day-14 cohort included more outpatients; after adjustment for setting, the Day-14 versus Day-28 odds ratio was non-significant (1.52; 95% CI 0.59–3.92; p=0.382; interaction p=0.145).
Conclusion
In this retrospective cohort study of 100 patients who received CAR-T therapy, 14-day monitoring after REMS elimination was not associated with increased early mortality, severe CRS, severe ICANS, infection, ICU admission, or inferior 90-day survival compared with 28-day monitoring. Although 30-day readmission was numerically higher in the Day-14 cohort, this difference was largely explained by treatment setting, with higher readmission rates in the outpatient setting.
These findings support the feasibility of a 14-day ATC monitoring model while underscoring the need for larger multicenter studies to confirm safety across disease indications, products, and care delivery models.
DISCLOSURES
Benjamin Hane: No relevant conflicts of interest to declare.